Doxylamine Succinate And Pyridoxine Hydrochloride Tablet, Delayed Release
Product Images NDC 70505-100

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Doxylamine Succinate And Pyridoxine Hydrochloride (NDC 70505-100). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Analog Pharma, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label-outside Front Cover With Imprint Area For Lot & Expiry (Bottle Label 1)

Label for Doxylamine Succinate and Pyridoxine Hydrochloride delayed-release tablets, 10 mg/10 mg, by Analog Pharma. The label states it contains 100 delayed-release tablets and includes warnings to swallow tablets whole without crushing, chewing, or splitting. Directions note the usual dosage and storage instructions. The product is distributed by Analog Pharma in Bryn Mawr, PA, and manufactured in Canada.*

FDA Label Image

Bottle Label – Inside Cover (Bottle Label Inside)

Label for Doxylamine Succinate and Pyridoxine Hydrochloride delayed-release tablets, 10 mg/10 mg strength, manufactured in Canada and distributed by Analog Pharma, Inc. The label indicates a package containing 100 delayed-release tablets. Storage instructions and pharmacist dispensing information are also shown, along with the Analog Pharma logo and the NDC number 70505-100-10.*

FDA Label Image

Structure-1 (Structure 1)

Chemical structure diagram showing the molecular formulas of doxylamine succinate and pyridoxine hydrochloride. The left structure represents doxylamine succinate with its characteristic aromatic rings, and the right structure shows pyridoxine hydrochloride components.*

FDA Label Image

Structure-2 (Structure 2)

Chemical structure diagram of pyridoxine hydrochloride, showing a pyridine ring with hydroxyl and methyl groups, complexed with hydrochloride (HCl). This corresponds to the pyridoxine hydrochloride component of the drug combination.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.